• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

遗传性发作性共济失调

Hereditary episodic ataxias.

作者信息

Jen Joanna C

机构信息

Department of Neurology, UCLA School of Medicine, Los Angeles, California 90095-1769, USA.

出版信息

Ann N Y Acad Sci. 2008 Oct;1142:250-3. doi: 10.1196/annals.1444.016.

DOI:10.1196/annals.1444.016
PMID:18990130
Abstract

Hereditary episodic ataxia (EA) syndromes are rare monogenic disorders that are phenotypically and genetically heterogeneous. The number of identified EA phenotypes is expanding. So far, mutations have been identified in four genes, all coding for membrane proteins including ion channels and transporters. The study of EA has illuminated previously unrecognized but important roles of ion channels and transporters in cerebellar function. This review summarizes recent advances and focuses on practical approaches in the diagnosis and treatment of episodic ataxia.

摘要

遗传性发作性共济失调(EA)综合征是罕见的单基因疾病,在表型和遗传上具有异质性。已确定的EA表型数量正在增加。到目前为止,已在四个基因中鉴定出突变,所有这些基因都编码膜蛋白,包括离子通道和转运蛋白。对EA的研究揭示了离子通道和转运蛋白在小脑功能中以前未被认识但很重要的作用。这篇综述总结了最近的进展,并重点关注发作性共济失调诊断和治疗的实用方法。

相似文献

1
Hereditary episodic ataxias.遗传性发作性共济失调
Ann N Y Acad Sci. 2008 Oct;1142:250-3. doi: 10.1196/annals.1444.016.
2
Episodic movement disorders as channelopathies.
Mov Disord. 2000 May;15(3):429-33.
3
Episodic ataxia associated with EAAT1 mutation C186S affecting glutamate reuptake.与影响谷氨酸再摄取的EAAT1突变C186S相关的发作性共济失调。
Arch Neurol. 2009 Jan;66(1):97-101. doi: 10.1001/archneurol.2008.535.
4
Muscle channelopathies.肌肉离子通道病
Semin Neurol. 2008 Apr;28(2):260-9. doi: 10.1055/s-2008-1062262.
5
[Hereditary episodic ataxia].[遗传性发作性共济失调]
Rev Neurol (Paris). 2011 May;167(5):401-7. doi: 10.1016/j.neurol.2010.10.016. Epub 2011 Apr 13.
6
Early-onset progressive ataxia associated with the first CACNA1A mutation identified within the I-II loop.早发性进行性共济失调与在I-II环内鉴定出的首个CACNA1A突变相关。
J Neurol Sci. 2007 Mar 15;254(1-2):69-71. doi: 10.1016/j.jns.2007.01.008. Epub 2007 Feb 12.
7
[The genetics of movement disorders--spinocerebellar degenerations].[运动障碍的遗传学——脊髓小脑变性]
Tidsskr Nor Laegeforen. 2004 Sep 9;124(17):2233-5.
8
Calcium channelopathies in inherited neurological disorders: relevance to drug screening for acquired channel disorders.遗传性神经疾病中的钙通道病:与获得性通道疾病药物筛选的相关性。
IDrugs. 2010 Jul;13(7):467-71.
9
Late-onset episodic ataxia type 2 due to an in-frame insertion in CACNA1A.由CACNA1A基因框内插入导致的迟发性发作性共济失调2型。
Neurology. 2005 Sep 27;65(6):944-6. doi: 10.1212/01.wnl.0000176069.64200.28.
10
[Episodic ataxias].[发作性共济失调]
Tidsskr Nor Laegeforen. 2005 Aug 11;125(15):2005-7.

引用本文的文献

1
Episodic ataxias in children and adolescents: Clinical findings and suggested diagnostic criteria.儿童和青少年发作性共济失调:临床发现及建议的诊断标准。
Front Neurol. 2022 Oct 24;13:1016856. doi: 10.3389/fneur.2022.1016856. eCollection 2022.
2
Microscopic Characterization of the Chloride Permeation Pathway in the Human Excitatory Amino Acid Transporter 1 (EAAT1).人类兴奋性氨基酸转运蛋白 1(EAAT1)中氯离子渗透途径的微观特征。
ACS Chem Neurosci. 2022 Mar 16;13(6):776-785. doi: 10.1021/acschemneuro.1c00769. Epub 2022 Feb 22.
3
Ataxia-linked SLC1A3 mutations alter EAAT1 chloride channel activity and glial regulation of CNS function.与共济失调相关的 SLC1A3 突变改变了 EAAT1 氯离子通道的活性和神经胶质对中枢神经系统功能的调节。
J Clin Invest. 2022 Apr 1;132(7). doi: 10.1172/JCI154891.
4
Therapeutic Potential of Sodium Channel Blockers as a Targeted Therapy Approach in -Associated Episodic Ataxia and a Comprehensive Review of the Literature.钠通道阻滞剂作为发作性共济失调相关靶向治疗方法的治疗潜力及文献综述
Front Neurol. 2021 Sep 9;12:703970. doi: 10.3389/fneur.2021.703970. eCollection 2021.
5
Aminopyridines and Acetyl-DL-leucine: New Therapies in Cerebellar Disorders.氨吡啶和乙酰-DL-亮氨酸:小脑疾病的新疗法。
Curr Neuropharmacol. 2019;17(1):7-13. doi: 10.2174/1570159X16666180905093535.
6
Restoring Axonal Function with 4-Aminopyridine: Clinical Efficacy in Multiple Sclerosis and Beyond.用 4-氨基吡啶恢复轴突功能:多发性硬化症及其他疾病的临床疗效。
CNS Drugs. 2018 Jul;32(7):637-651. doi: 10.1007/s40263-018-0536-2.
7
A novel mutation in SLC1A3 causes episodic ataxia.一种新型 SLC1A3 突变导致发作性共济失调。
J Hum Genet. 2018 Feb;63(2):207-211. doi: 10.1038/s10038-017-0365-z. Epub 2017 Dec 5.
8
Aminopyridines for the treatment of neurologic disorders.用于治疗神经系统疾病的氨基吡啶类药物。
Neurol Clin Pract. 2017 Feb;7(1):65-76. doi: 10.1212/CPJ.0000000000000321.
9
A CaV2.1 N-terminal fragment relieves the dominant-negative inhibition by an Episodic ataxia 2 mutant.一种CaV2.1 N端片段可缓解发作性共济失调2型突变体的显性负性抑制作用。
Neurobiol Dis. 2016 Sep;93:243-56. doi: 10.1016/j.nbd.2016.05.020. Epub 2016 May 31.
10
Update on the pharmacotherapy of cerebellar and central vestibular disorders.小脑和中枢性前庭疾病药物治疗的最新进展。
J Neurol. 2016 Apr;263 Suppl 1:S24-9. doi: 10.1007/s00415-015-7987-x. Epub 2016 Apr 15.